GCP
CNTX icon

GSA Capital Partners’s Context Therapeutics CNTX Stock Holding History

GSA Capital Partners’s Portfolio CNTX Stock Details CNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$89K Buy
+159,804
New +$324K 0.01% 1633
2025
Q1 		– Sell
-27,122
Closed -$28K – 1714
2024
Q4 		$28K Buy
+27,122
New +$46.9K ﹤0.01% 1550

Other funds holding CNTX

DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

GSA Capital Partners's CNTX Position: Q2 2026 in Review

GSA Capital Partners opened a new position in Context Therapeutics (CNTX) in Q2 2026: 159,804 shares worth $89K. The stake represents 0.01% of the portfolio and ranks #1633 among its holdings. This is a return to the name: GSA Capital Partners previously reported a position in CNTX as recently as Q4 2024.

GSA Capital Partners first reported a position in CNTX in Q4 2024 and has held it in 2 quarters since. 79 funds tracked by Wall St. Rank hold CNTX as of Q2 2026.

  • GSA Capital Partners held 159,804 shares of Context Therapeutics worth $89K as of Q2 2026.
  • Context Therapeutics was a new GSA Capital Partners position in Q2 2026.
  • Context Therapeutics made up 0.01% of GSA Capital Partners's portfolio in Q2 2026, its #1633 holding.
  • GSA Capital Partners first reported a position in Context Therapeutics in Q4 2024 and has held it in 2 quarters since.
  • 79 funds tracked by Wall St. Rank held Context Therapeutics as of Q2 2026.

Based on GSA Capital Partners's 13F filing for Q2 2026, filed 6 Aug 2026.